Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral Neuropathy (ENFORCE)

A Phase 3, Prospective, Adaptive, Randomized, Double-blind, Triple-masked, Parallel, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral Neuropathy

A phase 3, prospective, adaptive, randomized, multicenter, double-blind, triple-masked, parallel clinical trial to evaluate the efficacy and safety of N0750 in relieving pain associated with painful diabetic peripheral neuropathy (PDPN).

Study Overview

• Status: Withdrawn
• Conditions: Painful Diabetic Peripheral Neuropathy (PDPN)
• Intervention / Treatment: Drug: N0750; Drug: Cymbalta®; Drug: Lyrica®

Detailed Description

The objective of this clinical trial is to demonstrate the superiority of treatment with N0750 compared to monotherapy with Cymbalta® (duloxetine hydrochloride 60 mg, delayed-release capsule) and Lyrica® (pregabalin 150 mg, hard capsule, given twice daily for a total daily dose of 300 mg).

The clinical trial population will consist of patients of both sexes, diagnosed with PDPN for at least 3 months, confirmed by the presence of signs and symptoms in the Neuropathic Impairment Score (NIS) and Neuropathic Symptom Score (NSS), respectively, and with pain ≥ 6 points on the Numerical Scale (11 points [0-10]).

The primary objective of this clinical trial is to evaluate the reduction in pain intensity associated with Diabetic Peripheral Neuropathy (DPN). The primary endpoint of the trial is the change from baseline (Randomisation Visit [RV]) at the end of 12 weeks of treatment (Visit 4) in the weekly mean pain intensity in the last 24 hours, as assessed by the Numerical Rating Scale (11 points [0-10]).

• Study Type: Interventional
• Phase: Phase 3

Contacts and Locations

Study Locations

• Brazil
  • São Paulo
    • Itapevi, São Paulo, Brazil, 06696-000
      • Eurofarma Laboratórios S.A

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Ability to confirm voluntary participation and agree to all purposes of the trial, by signing and dating the Informed Consent Form (ICF) in two copies.
2. Subjects of both sexes, aged between 18 and 80 years.
3. Previous diagnosis of type 1 diabetes mellitus or type 2 diabetes mellitus.
4. Subjects diagnosed with PDPN for at least 3 months, confirmed by NSS ≥ 5 points and NIS ≥ 3 points.
5. Subjects who agree to discontinue current PDPN treatment during the washout period.
6. Subjects willing and able to comply with all study requirements, including completion of study diary and questionnaires.

Exclusion Criteria:

1. Painful peripheral neuropathy due to other causes, e.g. B12 and/or folate deficiency and hypothyroidism.
2. Previous diagnosis of other types of pain not related to PDPN, which at the Investigator's discretion, may confound the assessment of clinical trial endpoints, such as, but not limited to: peripheral vascular disease (ischemic pain); neurological disorders unrelated to diabetic neuropathy (phantom pain due to limb amputation); other painful conditions (e.g., arthritis).
3. Skin changes in the PDPN area that may cause changes in sensitivity or preclude physical assessment, e.g.: plantar ulcer.
4. Subjects with any other clinically significant clinical or laboratory change that, at the opinion Investigator's opinion make the subject unsuitable for trial participation.
5. Subjects with depression undergoing drug treatment or subjects with severe depression.
6. Subjects with a history of angioedema.
7. Subjects with a previous diagnosis of class III or IV heart failure according to the New York Heart Association criteria.
8. History of seizures.
9. Recent (<6 months) myocardial infarction.
10. Patients with increased intraocular pressure or who are at risk of closed-angle glaucoma.
11. Subjects at risk of suicide at the Investigator's discretion.
12. Prior treatment with chemotherapeutic agents that cause neuropathy, such as, but not limited to: platinum compounds (oxaliplatin, cisplatin and carboplatin) and taxanes (docetaxel and paclitaxel).
13. History of current alcohol or drug abuse or dependence.
14. Lack of response to prior treatment with pregabalin at doses ≥ 300 mg and/or duloxetine 60 mg.
15. Use of prohibited medications within 7 days prior to the Screening Visit or change in concomitant drugs within 30 days prior to the Screening Visit.
16. Use of prohibited concomitant medications that cannot be discontinued during participation in the clinical trial.
17. Subjects with any clinically significant condition, including serious psychiatric disorders, which at the Investigator's discretion make the subject unsuitable for trial participation.
18. History of any malignancy within the past 5 years, except successfully treated non-metastatic basal cell or squamous cell carcinoma of the skin.
19. Subjects who have participated in other clinical trials in the last 12 months, unless the investigator believes there may be a direct benefit to them.
20. Pregnant or breastfeeding female subjects or women of childbearing potential who do not agree to use contraception during the clinical trial.
21. Glycated hemoglobin ≥ 10.5%.
22. Subjects with severe renal impairment (estimated glomerular filtration rate based on creatinine by the CKD-EPI equation < 30 mL/min) and/or with severe liver disease (Aspartate Aminotransferase and Alanine Aminotransferase twice the reference value).
23. Clinically significant cardiac arrhythmias, second- or third-degree heart block, or left bundle branch block on 12-lead electrocardiogram (ECG).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: N0750; Phase 1 of the Dosage Titration: 3 capsules/day; Phase 2 of the Dosage Titration: 5 capsules/day; Treatment: 4 capsules/day; Withdrawal: 4 capsules/day	Drug: N0750; N0750 caps + Cymbalta placebo caps + Lyrica placebo caps
Active Comparator: Cymbalta®; Phase 1 of the Dosage Titration: 3 capsules/day; Phase 2 of the Dosage Titration: 5 capsules/day; Treatment: 4 capsules/day; Withdrawal: 4 capsules/day	Drug: Cymbalta®; Cymbalta® caps + N0750 placebo caps + Lyrica placebo caps
Active Comparator: Lyrica®; Phase 1 of the Dosage Titration: 3 capsules/day; Phase 2 of the Dosage Titration: 5 capsules/day; Treatment: 4 capsules/day; Withdrawal: 4 capsules/day	Drug: Lyrica®; Lyrica® caps + N0750 placebo caps + Cymbalta placebo caps

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of the efficacy of N0750 compared to Cymbalta® and Lyrica® in reducing pain intensity in patients with painful diabetic peripheral neuropathy	Change from baseline at the end of 12 weeks of treatment in the weekly average pain intensity in the last 24 hours using Numerical Rating Scale (11 points [0-10]), where higher scores mean a worse outcome.	84 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of the efficacy of N0750 compared to Cymbalta® and Lyrica® in reducing pain in patients with painful diabetic peripheral neuropathy	Change from baseline (VR) at each week of treatment (week 1 to week 12) in the weekly average pain intensity in the last 24 hours by the Numerical Rating Scale (11 points [0-10]). Proportion of subjects showing pain reduction ≥ 30% at the end of 12 weeks of treatment (V4) compared to baseline (VR). Proportion of subjects showing pain reduction ≥ 50% at the end of 12 weeks of treatment (V4) compared to baseline (VR).	84 days
Evaluation of the efficacy of N0750 compared to Cymbalta® and Lyrica® on subject perception of overall change in painful diabetic peripheral neuropathy	Change from baseline at the end of 12 weeks of treatment on the Patient Global Impression of Change questionnaire - PGIC-C (8 points [0-7]), where higher scores mean a better outcome.	84 days
Evaluate the safety profile of N0750 compared to Cymbalta® and Lyrica®	Frequency and intensity of AEs (Adverse Event), TEAEs (Treatment Emergent Adverse Event), SAEs (Serious adverse event). All safety analyses will be based on all subjects who received at least one dose of the trial treatments.	84 days

Collaborators and Investigators

• Sponsor: Eurofarma Laboratorios S.A.

Study record dates

Study Major Dates

• Study Start (Estimated): April 1, 2026
• Primary Completion (Estimated): March 1, 2028
• Study Completion (Estimated): March 1, 2028

Study Registration Dates

• First Submitted: November 26, 2024
• First Submitted That Met QC Criteria: November 28, 2024
• First Posted (Actual): December 4, 2024

Study Record Updates

• Last Update Posted (Actual): December 18, 2025
• Last Update Submitted That Met QC Criteria: December 11, 2025
• Last Verified: February 1, 2025

More Information

Terms related to this study

• Keywords: Diabetes; Pain; Diabetes Mellitus; Diabetes, Type 1; peripheral neuropathy; Diabetes Mellitus, Type 2; neuropathies; neuropathy; Diabetes Mellitus, Type 1; peripheral diabetic neuropathy; Peripheral Nervous System Diseases; diabetics; diabetic peripheral neuropathy; PDPN; peripheral; Diabetes, Type 2; diabetic neuropathy peripheral; peripheral neuropathies; Peripheral nerve damage
• Additional Relevant MeSH Terms: Neurologic Manifestations; Endocrine System Diseases; Nervous System Diseases; Neuromuscular Diseases; Metabolic Diseases; Autoimmune Diseases; Immune System Diseases; Glucose Metabolism Disorders; Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Signs and Symptoms; Pain; Diabetes Mellitus, Type 2; Diabetes Mellitus; Peripheral Nervous System Diseases; Diabetes Mellitus, Type 1; Neuritis; Amino Acids, Peptides, and Proteins; Sulfur Compounds; Organic Chemicals; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Acids, Acyclic; Carboxylic Acids; Amino Acids; gamma-Aminobutyric Acid; Aminobutyrates; Butyrates; Thiophenes; Duloxetine Hydrochloride; Pregabalin
• Other Study ID Numbers: EF188

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No